Welcome to our dedicated page for Allogene Therapeutics news (Ticker: ALLO), a resource for investors and traders seeking the latest updates and insights on Allogene Therapeutics stock.
Allogene Therapeutics, Inc. (Nasdaq: ALLO) is a clinical-stage biotechnology company developing allogeneic CAR T (AlloCAR T) therapies for cancer and autoimmune disease. The ALLO news feed on Stock Titan aggregates company announcements, clinical updates, and regulatory disclosures so readers can follow how its AlloCAR T pipeline progresses through development.
News about Allogene frequently highlights key milestones in its major programs. For oncology, updates include progress in the pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma, including trial design changes, site activations, and planned interim analyses focused on minimal residual disease (MRD) conversion. For autoimmune disease, releases cover the Phase 1 RESOLUTION trial of ALLO-329, a dual CD19/CD70 AlloCAR T candidate that incorporates the company’s Dagger® technology and is being studied across multiple rheumatologic indications.
Investors and observers can also find news on ALLO-316 in renal cell carcinoma through the TRAVERSE trial, including early clinical response data and discussions with regulators about potential pivotal development. Additional items include quarterly financial results, cash runway commentary, participation in investor and medical conferences, and 8-K summaries of material events such as changes in lymphodepletion strategy or intellectual property developments involving licensed TALEN-based gene-editing technology.
By following ALLO news, readers can track clinical catalysts, safety and biomarker findings, regulatory interactions, and corporate updates that may influence perceptions of Allogene’s AlloCAR T platform and its potential applications in hematologic malignancies, solid tumors, and autoimmune diseases.
Allogene Therapeutics (Nasdaq: ALLO) positioned 2026 as a program-defining year with multiple H1 clinical readouts aimed at validating off-the-shelf AlloCAR T across oncology and autoimmune disease. Key near-term milestones include an early Q2 2026 interim futility analysis of MRD clearance from the pivotal Phase 2 ALPHA3 trial of cema-cel in 1L consolidation LBCL and initial proof-of-concept data for ALLO-329 (dual CD19/CD70 with Dagger®) by end of 1H 2026. The platform targets manufacturing scale of ~30,000–60,000+ doses annually and a COGS profile of <$10K–20K per dose. ALLO-316 showed a 31% confirmed ORR in high CD70 RCC patients. Cash runway is expected into 2H 2027 (excludes BD activity).
Allogene (Nasdaq: ALLO) announced a favorable arbitration ruling that reconfirms its full development and commercial control of cemacabtagene ansegedleucel (cema-cel) in the United States, all EU member states, and the United Kingdom and clears a path to obtain full global commercialization rights from Servier.
The tribunal rejected Cellectis’s claims, found milestone payments tied to the pivotal trial are due only upon FDA acceptance of a BLA, and limited license termination to the UCART19 V1 product (ALLO-501). Allogene expects a meaningful catalyst with a 1H 2026 interim futility analysis from its pivotal Phase 2 ALPHA3 trial of cema-cel in 1L consolidation for large B-cell lymphoma (LBCL).
Allogene Therapeutics (Nasdaq: ALLO) will participate in three investor conferences in November and December 2025. Scheduled events:
- TD Cowen Immunology & Inflammation Virtual Summit — Wednesday, November 12 at 1:30 PM PT / 4:30 PM ET.
- Jefferies Global Healthcare Conference, London — Tuesday, November 18 at 2:00 AM PT / 5:00 AM ET / 10:00 AM GMT.
- Piper Sandler 37th Annual Healthcare Conference — Tuesday, December 2 at 9:00 AM PT / 12:00 PM ET.
Allogene Therapeutics (Nasdaq: ALLO) reported Q3 2025 results and provided program updates on November 6, 2025. Key financials: $277.1M in cash, cash equivalents and investments as of Sept 30, 2025, with cash runway projected into 2H 2027 and an expected 2025 cash decline of ~$150M. Q3 operating metrics: R&D $31.2M, G&A $13.7M, and net loss $41.4M ( $0.19/share). GAAP operating expenses guidance for 2025 is ~$230M including ~$45M stock-based comp.
Clinical milestones: pivotal Phase 2 ALPHA3 futility analysis (MRD conversion) on track for 1H 2026; ALLO-329 RESOLUTION PoC and biomarker update planned for 1H 2026; ALLO-316 showed durable responses in RCC and TRAVERSE completed Phase 1b enrollment.
Allogene (Nasdaq: ALLO) will present a Trial-in-Progress poster on the pivotal Phase 2 ALPHA3 study at the 2025 ASH Annual Meeting in Orlando.
ALPHA3 is a randomized, open-label trial testing cemacabtagene ansegedleucel (cema-cel) as a first-line consolidation for patients with large B-cell lymphoma (LBCL) who remain MRD-positive after 1L chemoimmunotherapy, comparing cema-cel after standard FC lymphodepletion versus observation. A futility analysis on MRD conversion is expected in 1H 2026. Poster: Session 628, Poster II, Publication 3730; presenter John Burke, MD; display on Dec 7, 2025, 6:00–8:00 PM ET at OCCC West Halls B3-B4.
Allogene Therapeutics (Nasdaq: ALLO) will report third quarter 2025 financial results and provide a business update on November 6, 2025 after market close. A live audio webcast and conference call is scheduled for 2:00 p.m. PT / 5:00 p.m. ET.
The listen-only webcast will be available via the company website under Investors > News and Events, and a replay will be posted for approximately 30 days. Investors who wish to ask questions must register for the conference call to receive a personal PIN to access the call.
Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotech company focused on developing allogeneic CAR T (AlloCAR T™) therapies for cancer and autoimmune diseases, has announced its participation in Citi's 2025 Biopharma Back to School Summit.
The presentation is scheduled for Wednesday, September 3, at 7:30 AM PT/10:30 AM ET. Investors can access the webcast through Allogene's website, with replays available for approximately 30 days after the event.
Allogene Therapeutics (Nasdaq: ALLO) reported Q2 2025 financial results and provided significant updates across its clinical pipeline. The company announced the advancement of its pivotal Phase 2 ALPHA3 trial for Cema-Cel in LBCL, now proceeding as a two-arm randomized study with over 50 activated sites. Additionally, Allogene initiated the Phase 1 RESOLUTION trial for ALLO-329 in autoimmune diseases and presented updated ALLO-316 results in renal cell carcinoma at ASCO 2025.
Financial highlights include a Q2 2025 net loss of $50.9 million ($0.23 per share) and a strong cash position of $302.6 million, extending runway into 2H 2027. R&D expenses were $40.2 million, while G&A expenses totaled $14.3 million for the quarter.
[ "Strong cash position of $302.6 million with runway extended into 2H 2027", "Successful expansion to over 50 clinical sites across U.S. and Canada for ALPHA3 trial", "FDA alignment achieved on pivotal trial design for ALLO-316 in solid tumors", "Launch of first autoimmune disease trial with ALLO-329" ]Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotech company focused on developing allogeneic CAR T (AlloCAR T™) therapies for cancer and autoimmune diseases, will release its Q2 2025 financial results on August 13, 2025 after market close.
The company will host a conference call and webcast at 2:00 PM PT/5:00 PM ET on the same day. Investors can access the webcast through Allogene's website, while those wishing to ask questions during the call must register separately to receive a personal PIN.
Allogene Therapeutics (NASDAQ:ALLO) has announced a significant change in its ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma. The company will proceed with standard fludarabine and cyclophosphamide (FC) lymphodepletion regimen, discontinuing the FC plus ALLO-647 (FCA) arm following a patient death attributed to ALLO-647.
The decision was made after a Grade 5 adverse event occurred on Day 54 post-infusion, resulting from hepatic failure due to disseminated adenovirus infection. The trial will now continue as a two-arm randomized study comparing cema-cel with standard FC lymphodepletion to observation. The scheduled futility analysis remains planned for 1H 2026.
Allogene is shifting its clinical strategy, removing ALLO-647 from all trials and advancing next-generation AlloCAR T products using their proprietary Dagger® Platform Technology, designed to minimize or eliminate standard lymphodepletion needs.
FAQ
What is the current stock price of Allogene Therapeutics (ALLO)?
What is the market cap of Allogene Therapeutics (ALLO)?
